News | August 12, 2009

Webcast Shows Use of Impella 2.5 in High-Risk PCI

August 12, 2009 – Abiomed Inc. said a webcast of an Impella 2.5 procedure performed on an 85-year-old man with multivessel disease at Mount Sinai Medical Center, now available and archived on the Abiomed Web site www.abiomed.com.

The webcast was broadcasted live from Mount Sinai Medical Center on July 21, 2009 and presents a successful high-risk percutaneous coronary intervention (PCI) case with Impella 2.5 support, performed by Samir Sharma, M.D., director of the catheterization lab and interventions, and Annapoorna Kini, M.D., associate professor of the cath lab at Mount Sinai Medical Center.

The patient, an 85-year-old male with multivessel disease, had a left ventricular ejection fraction (LVEF) of 20 percent, while normal LVEF typically ranges from 60–65 percent. Impella 2.5 was inserted to maintain left ventricular support and provide hemodynamic stability. “(Impella) gives operators the confidence to achieve good results without worrying about hemodynamic compromise,” said Dr. Sharma during the webcast.

For more information: www.abiomed.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init